0000000000890762

AUTHOR

Concettina La Motta

0000-0002-0194-5431

showing 1 related works from this author

Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d[pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2

2015

Vascular Endothelial Growth Factor (VEGF) pathway has emerged as one of the most important positive modulators of Angiogenesis, a central process implicated in tumour growth and metastatic dissemination. This led to the design and development of anti-VEGF monoclonal antibodies and small-molecule ATP-competitive VEGFR-inhibitors. In this study, we describe the synthesis and the biological evaluation of novel 2-aryl substituted benzothiopyrano-fused pyrimidines 1a-i, 2a-i and 3a-i. The ability of the compounds to target the VEGF pathway was determined in vitro exploiting the compounds' antiproliferative efficacy against HUVEC cells. The VEGFR-2 inhibition was confirmed by enzymatic assays on …

Models MolecularAngiogenesisReceptor tyrosine kinaseCellAntineoplastic AgentsReceptor tyrosine kinaseBenzothiopyranopirimidines; Kinase inhibitors; Receptor tyrosine kinases; Tumor angiogenesis; VEGFR;Tumor angiogenesisStructure-Activity Relationshipchemistry.chemical_compoundVEGFRBenzothiopyranopirimidineCell Line TumorReceptor tyrosine kinasesDrug DiscoveryHuman Umbilical Vein Endothelial CellsmedicineHumansProtein Kinase InhibitorsCell ProliferationPyransTumor angiogenesiPharmacologyKinase inhibitorDose-Response Relationship DrugMolecular StructurebiologyKinaseCell growthOrganic ChemistryKinase insert domain receptorGeneral MedicineVascular Endothelial Growth Factor Receptor-2Molecular biologyVascular endothelial growth factorPyrimidinesmedicine.anatomical_structureBenzothiopyranopirimidineschemistryBenzothiopyranopirimidines; Kinase inhibitors; Receptor tyrosine kinases; Tumor angiogenesis; VEGFRKinase inhibitorsCancer researchbiology.proteinDrug Screening Assays AntitumorEx vivo
researchProduct